The landscape of metabolic health continues evolving rapidly in 2026, with cagrilintide representing one of many promising developments
However, as of April 16, 2026 , the FDA and HHS officially reclassified BPC-157 and TB-500 as Category 1 Bulk Drug Substances
A.JanmeyP
Neither has completed Phase III clinical trials for hair growth or skin anti-aging endpoints in humans
Cagrilintide is an amylin analogue that works through the amylin/calcitonin receptor system
Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made